铁死亡诱导剂Erastin下调ACSL4抑制肝癌细胞体外增殖-CSCIED科技核心评价数据库-手机版

铁死亡诱导剂Erastin下调ACSL4抑制肝癌细胞体外增殖

Ferroptosis inducer Erastin inhibits proliferation of liver cancer cells in vitro by down-regulating ACSL4

ES评分 0 浏览量：55 下载量：0

DOI	10.12122/j.issn.1673-4254.2024.11.09
刊名	南方医科大学学报
年，卷(期)	2024, 44(11)
作者	赵培培1，2，周志刚3，杨媛媛1，2，黄树升1，2，涂逸轩4，涂剑1，2*,
作者单位	1桂林医学院药学院; 2广西肝脏损伤与修复分子医学重点实验室; 3桂林医学院第二附属医院麻醉科; 4暨南大学附属第一医院风湿免疫科
摘要	论文分析酯酰辅酶A合成酶长链家族成员4（ACSL4）在肝癌中的表达，探究铁死亡调控ACSL4对癌细胞增殖能力的影响。结果发现，相较于癌旁正常肝组织，肝癌组织中MDA含量降低，ACSL4、PCNA的mRNA和蛋白表达均显著增强；Erastin可抑制ACSL4、PCNA的mRNA和蛋白表达，并抑制细胞增殖、上调MDA含量；单独使用Fer-1对细胞存活率无影响；但加入Erastin后再应用Fer-1，则可逆转Erastin对ACSL4、PCNA表达，细胞增殖能力的抑制，MDA含量的上调。故得出结论，ACSL4在
Abstract	To investigate the expression of Acyl-CoA synthetase long-chain family member 4 (ACSL4) in liver cancer and its role in regulating ferroptosis and proliferation of liver cancer cells, MDA contents were lower and ACSL4 and PCNA expressions were higher sign
关键词	肝癌；细胞增殖；Erastin；ACSL4；铁死亡
KeyWord	liver cancer; cell proliferation; Erastin;Acyl-CoA synthetase long-chain family member 4; ferroptosis
基金项目
页码	2131-2136

参考文献
相关文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
[J]. CA Cancer J Clin, 2024, 74(3): 229-63.

[2] Yin Y, Feng WB, Chen J, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
[J]. Exp Hematol Oncol, 2024, 13(1): 72.

[3] Yi JZ, Li BB, Yin XM, et al. CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression
[J]. Oncol Res, 2024, 32(6): 1129-39.

[4] Li Y, Lu LQ, Tu J, et al. Reciprocal Regulation Between Forkhead Box M1/NF?κB and Methionine Adenosyltransferase 1A Drives Liver Cancer
[J]. Hepatology, 2020, 72(5): 1682-700.

[5] 刘叶琴, 周志刚, 杨明辉, 等. FOX家族促进肝纤维化的研究进展
[J]. 华夏医学, 2023, 36(6): 170-4.

[6] McGlynn KA, Petrick JL, Groopman JD. Liver Cancer: Progress and Priorities
[J]. Cancer Epidemiol Biomarkers Prev, 2024, 33(10): 1261-72.

[7] Zhu XY, Sha XD, Zang Y, et al. Current Progress of Ferroptosis Study in Hepatocellular Carcinoma
[J]. Int J Biol Sci, 2024, 20(9): 3621-37.

[8] Li SW, Zhang GX, Hu JK, et al. Ferroptosis at the nexus of metabolism and metabolic diseases
[J]. Theranostics, 2024, 14(15): 5826-52.

[9] Jiang YL, Yu YX, Pan ZY, et al. Ferroptosis: a new hunter of hepatocellular carcinoma
[J]. Cell Death Discov, 2024, 10(1): 136.

[10]Li XD, Meng FG, Wang HK, et al. Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma
[J]. Front Endocrinol (Lausanne), 2024, 14: 1319969.

[11]Liu RJ, Yu XD, Yan SS, et al. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)
[J]. Int J Oncol, 2024, 64(6): 63.

[12]葛树杰, 胡永全, 周晓静, 等. GPX4介导铁死亡在上皮性卵巢癌顺铂耐药细胞中的作用
[J].华夏医学, 2023, 36(4): 42-6.

[13]Xu QP, Ren LQ, Ren N, et al. Ferroptosis: a new promising target for hepatocellular carcinoma therapy
[J]. Mol Cell Biochem, 2024, 479(10): 2615-36.

[14]Zhang W, Jiang BP, Liu YX, et al. Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4
[J]. Free Radic Biol Med, 2022, 180: 75-84.

[15]Rochette L, Dogon G, Rigal E, et al. Lipid peroxidation and iron metabolism: Two corner stones in the homeostasis control of ferroptosis
[J]. Int J Mol Sci, 2022, 24 (1): 449.

[16]Nie JH, Lin BL, Zhou M, et al. Role of ferroptosis in hepatocellular carcinoma
[J]. J Cancer Res Clin Oncol, 2018, 144(12): 2329-37.

[17]Xu XT, Zhang XY, Wei CQ, et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis
[J]. Eur J Pharm Sci, 2020, 152: 105450.

[18]Yan XY, Liu YD, Li CC, et al. Pien-Tze-Huang prevents hepatocellular carcinoma by inducing ferroptosis via inhibiting SLC7A11-GSH-GPX4 axis
[J]. Cancer Cell Int, 2023, 23 (1): 109.

[19]Toshida K, Itoh S, Iseda N, et al. Impact of ACSL4 on the prognosis of hepatocellular carcinoma: Association with cancer-associated fibroblasts and the tumour immune microenvironment
[J]. Liver Int, 2024, 44(4): 1011-23.

[20]Zhang L, Luo YL, Xiang Y, et al. Ferroptosis inhibitors: past, present and future
[J]. Front Pharmacol, 2024, 15: 1407335.

[21]Ding KY, Liu CB, Li L, et al. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism
[J]. Chin Med J (Engl), 2023, 136(21): 2521-37.

[22]Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
[J]. Nature, 2017, 547(7664): 453-7.

[23]Wu DD, Zuo ZC, Sun XN, et al. ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription
[J]. Biochem Pharmacol, 2024, 224: 116206.

[24]Sun YW, Deng RR, Zhang CW. Erastin induces apoptotic and ferroptotic cell death by inducing ROS accumulation by causing mitochondrial dysfunction in gastric cancer cell HGC?27
[J]. Mol Med Rep, 2020, 22(4): 2826-32.

[25]Hang TD, Hung HM, Beckers P, et al. Structural investigation of human cystine/glutamate antiporter system xc?(Sxc?) using homology modeling and molecular dynamics
[J]. Front Mol Biosci, 2022, 9: 1064199.

[26]Cao JY, Dixon SJ. Mechanisms of ferroptosis
[J]. Cell Mol Life Sci, 2016, 73: 2195-209.

[27]Maeda H, Miura K, Aizawa K, et al. Apomorphine Suppresses the Progression of Steatohepatitis by Inhibiting Ferroptosis
[J]. Antioxidants (Basel), 2024, 13(7): 805.

[28]Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron dependent form of nonapoptotic cell death
[J]. Cell, 2012, 149 (5): 1060-72.

[29]Chu J, Liu CX, Song R, et al. Ferrostatin-1 protects HT-22 cells from oxidative toxicity
[J]. Neural Regen Res, 2020, 15(3): 528-36.

[30]Tao L, Yang XQ, Ge CD, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
[J]. Cell Metab, 2024, 36(10): 2190-206.

引用本文

赵培培，，周志刚，杨媛媛，，黄树升，，涂逸轩，涂剑，*. 铁死亡诱导剂Erastin下调ACSL4抑制肝癌细胞体外增殖 [J]. 南方医科大学学报. 2024; 44; (11). 2131 - 2136.

文献评论

相关学者

相关机构